ENDRA Life Sciences Inc
ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is involved in the development of thermo-acoustic enhanced ultrasound technology that uses pulsed energy source comprising radio frequency to transmit energy deep into tissue and generate ultrasonic waves to create high-contrast images for use in the treatment of non-alcoholic… Read more
ENDRA Life Sciences Inc (NDRA) - Total Assets
Latest total assets as of September 2025: $1.96 Million USD
Based on the latest financial reports, ENDRA Life Sciences Inc (NDRA) holds total assets worth $1.96 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
ENDRA Life Sciences Inc - Total Assets Trend (2014–2024)
This chart illustrates how ENDRA Life Sciences Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
ENDRA Life Sciences Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
ENDRA Life Sciences Inc's total assets of $1.96 Million consist of 77.1% current assets and 22.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 72.5% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2014–2024)
This chart illustrates how ENDRA Life Sciences Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: ENDRA Life Sciences Inc's current assets represent 77.1% of total assets in 2024, an increase from 57.5% in 2014.
- Cash Position: Cash and equivalents constituted 72.5% of total assets in 2024, up from 22.3% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2014.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
ENDRA Life Sciences Inc Competitors by Total Assets
Key competitors of ENDRA Life Sciences Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ADCNF
OTCGREY:ADCNF
|
USA | $4.51 Billion |
|
Berry Genomics Co Ltd
SHE:000710
|
China | CN¥2.34 Billion |
|
Malaysian Genomics Resource
KLSE:0155
|
Malaysia | RM20.70 Million |
|
NSN Co. Ltd
KQ:031860
|
Korea | ₩60.96 Billion |
|
JOONGANG DNM Co.Ltd
KQ:051980
|
Korea | ₩121.79 Billion |
|
GeneMatrix Inc
KQ:109820
|
Korea | ₩28.03 Billion |
|
Genoray Co. Ltd
KQ:122310
|
Korea | ₩125.67 Billion |
|
Green Cross Lab Cell Corporation
KQ:144510
|
Korea | ₩565.79 Billion |
ENDRA Life Sciences Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - ENDRA Life Sciences Inc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - ENDRA Life Sciences Inc is currently not profitable relative to its asset base.
ENDRA Life Sciences Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.31 | 6.10 | 8.32 |
| Quick Ratio | 1.31 | 2.76 | 7.72 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $248.40K | $ 4.15 Million | $ 7.22 Million |
ENDRA Life Sciences Inc - Advanced Valuation Insights
This section examines the relationship between ENDRA Life Sciences Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 27.16 |
| Latest Market Cap to Assets Ratio | 0.82 |
| Asset Growth Rate (YoY) | -34.1% |
| Total Assets | $4.45 Million |
| Market Capitalization | $3.64 Million USD |
Valuation Analysis
Near Book Valuation: The market values ENDRA Life Sciences Inc's assets close to their book value ( 0.82x), suggesting investors view the company's assets at approximately fair value.
Significant Asset Reduction: ENDRA Life Sciences Inc's assets decreased by 34.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for ENDRA Life Sciences Inc (2014–2024)
The table below shows the annual total assets of ENDRA Life Sciences Inc from 2014 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $4.45 Million | -34.08% |
| 2023-12-31 | $6.75 Million | -27.17% |
| 2022-12-31 | $9.27 Million | -27.97% |
| 2021-12-31 | $12.87 Million | +46.89% |
| 2020-12-31 | $8.76 Million | +22.14% |
| 2019-12-31 | $7.18 Million | -0.64% |
| 2018-12-31 | $7.22 Million | +17.95% |
| 2017-12-31 | $6.12 Million | +1147.80% |
| 2016-12-31 | $490.76K | +0.83% |
| 2015-12-31 | $486.72K | -30.76% |
| 2014-12-31 | $702.93K | -- |